KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Titel:
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Auteur:
Maio, Michele Carlino, Matteo S. Joshua, Anthony M. McWhirter, Elaine Ribas, Antoni Ascierto, Paolo A. Miller Jr., Wilson H. Butler, Marcus O. Ferrucci, Pier Francesco Zielinski, Robert R. Del Vecchio, Michele Gasal, Eduard Ghori, Razi Diede, Scott J. Croydon, Elizabeth Hamid, Omid